Eli Lilly CEO: 700,000 Seniors Started GLP-1s Under Medicare
Medicare's GLP-1 coverage, launched in July, has driven 700,000 new senior users, with 70% choosing Lilly drugs, the CEO says.
Some 700,000 Medicare-eligible seniors have begun taking GLP-1 medications since the federal program expanded coverage for the drug class in July, Eli Lilly's chief executive disclosed, offering the clearest picture yet of how the policy shift is reshaping prescription patterns among older Americans.
Of those newly covered patients, roughly 70% are taking Lilly-branded GLP-1 therapies, according to the CEO's remarks — a market-share figure that underscores the Indiana-based drugmaker's dominant position in a category that has reshaped the pharmaceutical landscape in recent years.
Read more AI Kill Switch Debate: Policymakers Weigh Emergency Shutdown Options →
The data points arrive as policymakers and industry analysts continue to assess the real-world impact of extending Medicare access to GLP-1 drugs, which had long been restricted under the program. The coverage expansion was widely anticipated to unlock a large pool of potential patients among the senior population, which historically has faced higher rates of obesity and related metabolic conditions.
For Lilly, the early enrollment numbers represent a significant commercial tailwind at a time when the company has been racing to scale manufacturing capacity to meet surging global demand. The 70% share among new Medicare starters suggests the company has successfully converted expanded access into tangible prescription volume, though competition in the GLP-1 space remains intense.
Continue reading at US Top News and Analysis.
